Large differences are observed in chemotherapy response between breast cancer patients,
with a substantial part of this variability being explained by genetic factors. Polymorphisms in …

Clinical and histopathologic characteristics of breast cancer have long played an important
role in treatment decision-making. Well-recognized prognostic factors include tumor size …

Breast cancer is the second most common cause of cancer-related death in women in the
US and the UK, accounting for 15–17% of all female cancer deaths. Current treatment …

Pharmacogenomics is the study of genetic variations between individuals to predict the risk
of toxic side effects and the probability that a patient will respond to single-or multidrug …

Carcinoma of the breast remains the most prevalent cancer diagnosed in women in the
world. Although breast cancer mortality has declined in the last two decades, breast cancer …

Increased understanding of how variants in genes encoding metabolising enzymes,
transporters and receptors affect drug efficacy and toxicity, in parallel with advances in …

Germline variants can be used to study breast cancer susceptibility as well as the variable
response to both drug and radiation therapy used in the treatment of breast cancer. In …

Among patients receiving adjuvant therapy for breast cancer, there is variability in treatment
outcomes, and it is unclear which patients will receive the most benefit from treatment and …

Breast cancer is the most common female cancer, with more than one million new patients
diagnosed annually worldwide. The great heterogeneity, in terms of prognosis and outcome …

Introduction: Breast cancer has benefited from a number of innovative therapeutics over the
last decade. Cytotoxics, hormone therapy, targeted therapies and biologics can now be …